公开(公告)号：US10519183B2

公开(公告)日：2019-12-31

申请号：US16096119

申请日：2017-03-27

申请人： Youngene Therapeutics Co., Ltd.

发明人： Lei Zhang ,  Yuan Wang

IPC分类号： C07H15/00 ,  C07H15/04 ,  C07H9/04 ,  C07H7/04 ,  C07H19/01 ,  A61K31/7048 ,  C07H1/00

摘要： Disclosed are an amine solvate of a sodium-glucose linked transporter (SGLT) inhibitor, and a preparation method and application thereof. The SGLT inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylbenzyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol. Further provided is a crystalline compound of the amine solvate, a pharmaceutical composition comprising the amine solvate, and an application of the amine solvate in preparing an SGLT-inhibiting pharmaceutical product.

公开(公告)号：US20190135848A1

公开(公告)日：2019-05-09

申请号：US16096119

申请日：2017-03-27

申请人： Youngene Therapeutics Co., Ltd.

发明人： Lei Zhang ,  Yuan Wang

IPC分类号： C07H19/01

摘要： Disclosed are an amine solvate of a sodium-glucose linked transporter (SGLT) inhibitor, and a preparation method and application thereof. The SGLT inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylbenzyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol. Further provided is a crystalline compound of the amine solvate, a pharmaceutical composition comprising the amine solvate, and an application of the amine solvate in preparing an SGLT-inhibiting pharmaceutical product.

公开(公告)号：US10011627B2

公开(公告)日：2018-07-03

申请号：US14917792

申请日：2014-08-19

申请人： YOUNGENE THERAPEUTICS CO., LTD

发明人： Huijuan Zhong ,  Jianchun Liao ,  Hongping Yu ,  Yaochang Xu ,  Qing Li ,  Jianghua Chen ,  Peng Gao ,  Songliang Tan ,  Shaobao Wang

IPC分类号： C07H7/06 ,  C07H9/04 ,  C07D409/10 ,  C07D409/14 ,  A61K31/00 ,  C07H7/04 ,  A61K31/7048 ,  C07D493/08

CPC分类号： C07H7/06 ,  A61K31/00 ,  A61K31/7048 ,  C07D409/10 ,  C07D409/14 ,  C07D493/08 ,  C07H7/04 ,  C07H9/04

摘要： C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of the compounds, preparation methods thereof, pharmaceutical compositions containing the compounds, and applications thereof are described. Compounds of formula (I) are useful as therapeutic agents, and particularly as sodium-dependent glucose contransporter protein (SGLT) inhibitors.